TARSUS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
TARSUS PHARMACEUTICALS, INC. (TARS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-09-30 was 0.00%.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-06-30 was 0.00%.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 0.00% 10-K · filed 2026-02-23 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 0.00% 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | 0.00% 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | 0.00% 10-K · filed 2025-02-25 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-13 | 0.00% 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | 0.00% 10-Q · filed 2024-08-08 | 0.00% 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 0.00% 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | 0.00% 10-K · filed 2025-02-25 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-13 | 0.00% 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-08 | 0.00% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 0.00% 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | 0.00% 10-K · filed 2025-02-25 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-09 | 0.00% 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-10 | 0.00% 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-17 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-14 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2020-11-25 | |||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |